BrainsWay Appoints Richard A. Bermudes, M.D.

Core Insights - BrainsWay Ltd. has appointed Richard A. Bermudes, M.D. as Chief Medical Officer effective September 1, 2024, succeeding Dr. Aron Tendler, M.D. who will continue to collaborate on strategic research projects [1][2] Company Overview - BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology [3] - The company has obtained three FDA-cleared indications for Deep TMS, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies demonstrating efficacy [3] - Founded in 2003, BrainsWay is committed to increasing global awareness and access to Deep TMS, with offices in Burlington, MA, and Jerusalem, Israel [3] Leadership and Expertise - Dr. Richard A. Bermudes brings over 20 years of experience in TMS and brain stimulation therapies, having co-founded a behavioral health care network and launched successful telehealth programs [2] - Dr. Bermudes is recognized as a leading clinician in the TMS field and has made significant academic contributions, including editing a notable book on clinical applications of transcranial magnetic stimulation [2]